Vaxcell-Bio Therapeutics Co., Ltd.
Financials
Valuation Metrics
Vaxcell-Bio Therapeutics Co., Ltd.'s Market Cap is ₩986B. At end of 2025 it was ₩2323B. Ranked #1290 of 2,421 in KR market (top 53%), #708 of 1,640 on KOSDAQ (top 43%), #143 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 62%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 98.61B KRW | KR#1,290/2,421 Sec#143/231 |
| Revenue | 6.51B KRW | KR#2,319/2,421 Sec#186/231 |
| Net Income | -14.92B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 66.90B KRW | KR#2,044/2,421 Sec#173/231 |
| Net Assets | 61.13B KRW | KR#1,773/2,421 Sec#151/231 |
| Employees | 81 | KR#1,803/2,421 Sec#150/231 |
| Value | ||
| P/B | 1.61x | KR#1,816/2,421 Sec#129/231 |
| P/S | 15.15x | KR#2,318/2,421 Sec#177/231 |
| FCF Yield | -16.91% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -24.40% | KR#2,136/2,421 Sec#167/231 |
| ROA | -22.30% | KR#2,262/2,421 Sec#182/231 |
| Op. Margin | -257.06% | KR#2,343/2,421 Sec#189/231 |
| Revenue Growth | 17.35% | KR#617/2,421 Sec#56/231 |
| Financial Health | ||
| Debt Ratio | 9.44% | KR#125/2,421 Sec#27/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | -16.67B KRW | KR#1,851/2,421 Sec#173/231 |
| Cash | 6.22B KRW | KR#1,920/2,421 Sec#170/231 |
| Current Ratio | 5.56x | KR#247/2,421 Sec#46/231 |
| Performance | ||
| 1Y Return | -54.41% | KR#2,134/2,421 Sec#198/231 |
| 1M Return | 5.34% | KR#726/2,421 Sec#53/231 |
| From 52W High | -63.19% | KR#1,974/2,421 Sec#159/231 |
| 1Y MDD | -67.41% | KR#1,857/2,421 Sec#155/231 |
| Trading | ||
| Volume | 88,569 shares | KR#838/2,421 Sec#77/231 |
| Trading Value | 377.8M KRW | KR#1,045/2,421 Sec#105/231 |
| Foreign Own. | 5.58% | KR#781/2,421 Sec#72/231 |
| Per Share | ||
| EPS | -641 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,628 KRW | KR#1,933/2,421 Sec#151/231 |
Company Info
Established in 2010 as a specialized company for developing anticancer immunotherapeutics, the company was listed on the KOSDAQ market in 2020. It has built diverse pipelines, including the innate immune system-based Vax-NK anticancer immunotherapy platform, the next-generation Vax-CAR series platform, small molecule compound targeted anticancer drugs, bispecific antibody new drugs, DDS-based drug development, and a pet healthcare business. The company continuously innovates to realize its vision of a better world through immunotherapies, focusing on key elements of the immune system. Vaxcell-Bio was established in 2010 and is headquartered in Jeollanam-do, Hwasun-gun.